Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion

'Transformative transaction' for Roivant gives Roche rights to promising inflammatory bowel disease treatment
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.